Table 14.3.1.2a Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Controlled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=7)			rhNGF 20 µg/ml (N=7)			Vehicle Control (N=4)			Total (N=18)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Any Adverse Events	8	3	(42.9%)	28	5	(71.4%)	11	4	(100.0%)	47	12	(66.7%)
Eye disorders	4	2	(28.6%)	16	4	(57.1%)	9	2	(50.0%)	29	8	(44.4%)
Eye pain	0	0		5	3	(42.9%)	2	1	(25.0%)	7	4	(22.2%)
Eye inflammation	0	0		2	2	(28.6%)	1	1	(25.0%)	3	3	(16.7%)
Visual acuity reduced	1	1	(14.3%)	1	1	(14.3%)	1	1	(25.0%)	3	3	(16.7%)
Photophobia	0	0		2	2	(28.6%)	0	0		2	2	(11.1%)
Conjunctival hyperaemia	2	1	(14.3%)	0	0		0	0		2	1	(5.6%)
Corneal epithelium defect	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Corneal lesion	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)
Dry eye	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Erythema of eyelid	1	1	(14.3%)	0	0		0	0		1	1	(5.6%)
Eye irritation	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Eyelid margin crusting	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)
Foreign body sensation in eyes	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)
Iridocyclitis	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Photopsia	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)
Ulcerative keratitis	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Vision blurred	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1a

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2a Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Controlled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=7)			rhNGF 20 µg/ml (N=7)			Vehicle Control (N=4)			Total (N=18)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Eye disorders												
Vitreous haemorrhage	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
General disorders and administration site conditions	2	2	(28.6%)	3	2	(28.6%)	1	1	(25.0%)	6	5	(27.8%)
Disease progression	2	2	(28.6%)	0	0		1	1	(25.0%)	3	3	(16.7%)
Fatigue	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Instillation site pruritus	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Irritability	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Infections and infestations	0	0		1	1	(14.3%)	1	1	(25.0%)	2	2	(11.1%)
Influenza	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Keratitis herpetic	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)
Investigations	2	1	(14.3%)	1	1	(14.3%)	0	0		3	2	(11.1%)
Haematocrit decreased	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Intraocular pressure increased	2	1	(14.3%)	0	0		0	0		2	1	(5.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1a

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2a Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Controlled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=7)			rhNGF 20 µg/ml (N=7)			Vehicle Control (N=4)			Total (N=18)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Nervous system disorders	0	0		2	2	(28.6%)	0	0		2	2	(11.1%)
Headache	0	0		2	2	(28.6%)	0	0		2	2	(11.1%)
Psychiatric disorders	0	0		3	2	(28.6%)	0	0		3	2	(11.1%)
Insomnia	0	0		2	2	(28.6%)	0	0		2	2	(11.1%)
Anxiety	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Cardiac disorders	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Cardiovascular disorder	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Musculoskeletal and connective tissue disorders	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Muscle spasms	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1a

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2a Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Uncontrolled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=0)			rhNGF 20 µg/ml (N=0)			Total (N=0)		
	N*	n	%	N*	n	%	N*	n	%
Any Adverse Events	0	0		0	0		0	0	

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1a

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2a Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=7)			rhNGF 20 µg/ml (N=7)			Vehicle Control (N=4)			Total (N=18)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Any Adverse Events	5	4	(57.1%)	12	2	(28.6%)	5	2	(50.0%)	22	8	(44.4%)
Eye disorders	3	2	(28.6%)	8	2	(28.6%)	1	1	(25.0%)	12	5	(27.8%)
Visual acuity reduced	3	2	(28.6%)	0	0		0	0		3	2	(11.1%)
Corneal decompensation	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Corneal epithelium defect	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Corneal oedema	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Dry eye	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Eye pain	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Keratitis	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Ocular hyperaemia	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)
Photophobia	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Retinal haemorrhage	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
General disorders and administration site conditions	2	2	(28.6%)	0	0		1	1	(25.0%)	3	3	(16.7%)
Disease progression	2	2	(28.6%)	0	0		1	1	(25.0%)	3	3	(16.7%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.
The data presented in this Table are contained in Listing 16.2.7.1a

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2a Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=7)			rhNGF 20 µg/ml (N=7)			Vehicle Control (N=4)			Total (N=18)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Nervous system disorders	0	0		2	2	(28.6%)	0	0		2	2	(11.1%)
Headache	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Hypoaesthesia	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Cardiac disorders	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Myocardial infarction	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Infections and infestations	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Corneal infection	0	0		1	1	(14.3%)	0	0		1	1	(5.6%)
Injury, poisoning and procedural complications	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)
Femur fracture	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)
Renal and urinary disorders	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)
Renal failure	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)
Respiratory, thoracic and mediastinal disorders	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)
Pulmonary oedema	0	0		0	0		1	1	(25.0%)	1	1	(5.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.
The data presented in this Table are contained in Listing 16.2.7.1a

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42